Abstract:Myeloid neoplasms (MN) are neoplastic diseases caused by the clonal proliferation of myeloid cells, which usually involve the bone marrow and affect blood cells, thus affecting the functions of other systems and even leading to short-term death. The diagnosis of MN is complicated, mainly relying on the World Health Organization (WHO) tumor classification. [ 1 , 2 ] Next-generation sequencing (NGS), as a high-throughput technology, can sequence DNA or RNA quickly and cost-effectively, making it suitable for simultaneous detection of multiple genetic abnormalities in MN. The sequence variants/mutations it detects are widely used in MN diagnosis, prognosis, treatment decisions, and patient follow-up. [ 3 ] Since the publication of the revised 4th edition of the WHO classification of hematolymphoid tumors (WHO-HAEM4R) in 2016, NGS mutation analysis has become common in clinical practice. The basis for MN classification continues to evolve as new pathological features are discovered and new therapies become available. Therefore, the World Health Organization released the fifth edition of the World Health Organization Classification of Hemolymph Neoplasms (WHO-HAEM5) on June 22, 2022. [ 4 ] Shortly thereafter, the Clinical Advisory Committee launched the International Consensus Classification (ICC) of hematologic neoplasms. [ 5 ] The ICC classification of specific MN categories was then introduced in detail, such as acute myeloid leukemia (AML), [ 6 ] myelodysplastic syndrome (MDS), [ 7 ] myeloproliferative neoplasm (MPN), [ 8 ] myelodysplasia/myeloproliferative neoplasms (MDS)/MPN), [ 9 ] published in Virchows Arch. Therefore, WHO-HAEM4R was updated to 2 different versions at the same time. There are inevitably differences between the 2, and both the classification algorithm and the classification results need to be fully understood. [ 10 ] To this end, we used WHO-HAEM5 and ICC to reclassify MN cases previously diagnosed according to WHO-HAEM4R to explore the practical significance of these 2 latest classification systems. We endeavored to carefully examine the contribution of these NGS-detected mutation signatures to both classifications. This is very useful for everyone to understand the different effects of the 2 new classifications in practical applications.

Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms – a practical guide to WHO HAEM5

Genetic alterations in lymphoblastic leukaemia / lymphoma – a practical guide to WHO HAEM5

Overview on WHO-HAEM5 and the diagnostic relevance of genetic alterations for the classification

Genetic studies in clonal haematopoiesis, myelodysplastic neoplasms and acute myeloid leukaemia – a practical guide to WHO-HAEM5

Genetic alterations in mature B- and T-cell lymphomas – a practical guide to WHO-HAEM5

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5

The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors – an overview and update

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research

Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts

The Fifth Edition of the World Health Organization Classification and the International Consensus Classification of Myeloid Neoplasms: Evolving Guidelines in the Molecular Era with Practical Implications

The fifth edition of the WHO-Classification - what is new for cutaneous lymphomas?

Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms

What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

[Interpretation of T-cell and NK-cell lymphoid proliferations and lymphomas in the 5th edition of the WHO classification of haematolymphoid tumours].

A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas

NGS panel enhance precise diagnosis of myeloid neoplasms under WHO-HAEM5 and International Consensus Classification: An observational study

Advances towards genome‐based acute myeloid leukemia classification: A comparative analysis of WHO‐HAEM4R, WHO‐HAEM5, and International Consensus Classification

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification